Back Hepatitis C

Hepatitis C

AASLD 2015: Daclatasvir + Sofosbuvir with Ribavirin Cures 90% of Genotype 3 Hepatitis C Patients

An all-oral combination of daclatasvir, sofosbuvir, and ribavirin taken for 12 or 16 weeks led to high sustained virological response rates for people with hard-to-treat hepatitis C virus (HCV) genotype 3 and advanced liver fibrosis or cirrhosis, according to findings from the ALLY-3+ study presented at the 2015 AASLD Liver Meeting this week in San Francisco.

alt

AASLD 2015: Daclatasvir + Sofosbuvir Works Well for Genotype 3 HCV Patients with Advanced Disease

Interferon-free treatment with daclatasvir plus sofosbuvir, with or without ribavirin, led to sustained virological response in a majority of patients with genotype 3 hepatitis C virus (HCV) and advanced liver disease treated in a real-world setting in compassionate use programs in Europe, according to a pair of studies presented at the 2015 AASLD Liver Meeting this week in San Francisco.

alt

AASLD 2015: Sofosbuvir/ Ledipasvir + Vedroprevir Cures 96% of Cirrhotic Genotype 1 Patients

A triple combination of Gilead Sciences' sofosbuvir/ledipasvir (Harvoni) plus the experimental HCV protease inhibitor vedroprevir cured 96% of treatment-experienced, cirrhotic, genotype 1 hepatitis C patients without the need for ribavirin, according to study findings presented at the AASLD Liver Meeting this week in San Francisco.

alt

AASLD 2015: Intensification with Sofosbuvir Permits Cure after Previous HCV Treatment Failure

Re-treating with an interferon-free regimen that previously failed to cure hepatitis C can result in success if treatment is intensified with the addition of sofosbuvir (Sovaldi), a pair of studies presented at the AASLD Liver Meeting this week in San Francisco have shown.

alt

AASLD 2015: New AbbVie Hepatitis C Combination Cures Up to 97% with Genotype 3

A combination of 2 experimental direct-acting antivirals developed by AbbVie cured 83%-97% of people with genotype 3 hepatitis C after a 12-week course of treatment, Paul Kwo from Indiana University School of Medicine reported at the 2015 AASLD Liver Meeting this week in San Francisco.

alt

FDA Expands Harvoni Indication to Include Hepatitis C Genotypes 4-6 and HIV/HCV Coinfection

The U.S. Food and Drug Administration last week granted supplemental approval of Gilead Sciences' sofosbuvir/ledipasvir (Harvoni) single-tablet regimen for the treatment of hepatitis C virus genotypes 4, 5, and 6 and for HIV/HCV coinfected people. The FDA also said Harvoni plus ribavirin for 12 weeks is an alternative to a 24 weeks of Harvoni alone for treatment-experienced hepatitis C patients with liver cirrhosis.

alt

AASLD 2015: Sofosbuvir + Ravidasvir Shows High Response Rates for Genotype 4 Hepatitis C

A regimen of sofosbuvir and the pan-genotypic HCV NS5A inhibitor ravidasvir, with or without ribavirin, demonstrated sustained response rates ranging from 86% to 100% in the largest Phase 3 trial to date of interferon-free treatment for people with hepatitis C virus genotype 4, according to study findings presented at the 2015 AASLD Liver Meeting taking place this week in San Francisco.

alt

AASLD 2015: Liver Fibrosis Improves after Successful Treatment for Chronic Hepatitis C

A majority of chronic hepatitis C patients with advanced fibrosis or cirrhosis showed improvement in liver health following treatment, according to study findings presented at the 2015 AASLD Liver Meeting this week in San Francisco. However, the researchers identified few demographic, laboratory, or disease-related factors that could predict who would experience fibrosis regression and who would have worsening liver damage.

alt

AASLD 2015: New AbbVie Pangenotypic Regimen Cures 97%-100% of Hepatitis C Patients in Early Study

A combination of 2 experimental direct-acting antivirals developed by AbbVie cured 97% to 100% of non-cirrhotic people with genotype 1 hepatitis C in a mid-stage Phase 2 study presented this week at the AASLD Liver Meeting in San Francisco.

alt